On 17 February, SciSparc Ltd., a clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced it has signed an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase II clinical trial in Alzheimer's disease (AD).
The purpose of the study is to evaluate the safety, tolerability and efficacy of SCI-110 in 110 people with AD and agitation. The primary objective of the study is the safety of SCI-110 and the secondary objective is the ability of the drug candidate to ameliorate agitation and other behavioral disturbances in people with AD. The company plans to initiate the trial immediately after receipt of all the required approvals.
